This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:ProShares Ultra Financials Fund (Symbol: UYG) Class Action Filed by Bernstein Liebhard LLP 2009-10-13 15:31 ET - News Release NEW YORK, NY
-- (MARKET WIRE)
-- 10/13/09 
Bernstein Liebhard LLP filed a class action
lawsuit on October 13, 2009 in the United States District Court for the
Southern District of New York, on behalf of all persons who purchased or
otherwise acquired shares in the Ultra Financials Fund (the "UYG Fund")
(NYSE: UYG), an exchange-traded fund ("ETF") offered by ProShares Trust
("ProShares"), pursuant or traceable to ProShares' false and misleading
Registration Statement, Prospectuses, and Statements of Additional
Information (collectively, the "Registration Statement") issued in
connection with shares of the UYG Fund (the "Class"). The Class is seeking
to pursue remedies under Sections 11 and 15 of the Securities Act of 1933
(the "Securities Act").
The complaint names ProShares, ProShare Advisors LLC, SEI Investments
Distribution Co., Michael L. Sapir, Louis M. Mayberg, Russell S. Reynolds,
III, Michael Wachs, and Simon D. Collier, as defendants (collectively,
"Defendants"). ProShares sells its Ultra and UltraShort ETFs as "simple"
directional plays. As marketed by ProShares, Ultra ETFs are designed to go
up when markets go up; UltraShort ETFs are designed to go up when markets
go down. The UYG Fund is one of ProShares' Ultra ETFs. The UYG Fund seeks
investment results that correspond to twice (+200%) the daily performance
of the Dow Jones U.S. Financial Index ("DJUSFI"). Accordingly, the UYG
Fund is supposed to deliver double the return of the DJUSFI, which, from
January 1, 2009 through July 30, 2009, increased approximately 1.47
percent. Rather than increase approximately 2.9 percent (double), the UYG
Fund has fallen approximately 25 percent.
The remainder is available to Stockwatch subscribers. If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |